MedPath

Sichuan Academy of Medical Sciences

🇨🇳China
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:1
Completed:2

Trial Phases

2 Phases

Phase 4:2
Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (60.0%)
Phase 4
2 (40.0%)

Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

Phase 4
Not yet recruiting
Conditions
Essential Hypertension
Type 2 Diabetes
Nephropathy
Interventions
First Posted Date
2024-07-15
Last Posted Date
2024-07-15
Lead Sponsor
Sichuan Academy of Medical Sciences
Target Recruit Count
297
Registration Number
NCT06501651
Locations
🇨🇳

Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Not Applicable
Recruiting
Conditions
Peritoneal Dialysis Complication
Renal Function Aggravated
Sodium-glucose Co-transporter-2 Inhibitors
Interventions
First Posted Date
2024-05-03
Last Posted Date
2024-05-03
Lead Sponsor
Sichuan Academy of Medical Sciences
Target Recruit Count
70
Registration Number
NCT06398977
Locations
🇨🇳

Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospita, Chengdu, Sichuan, China

Exercise Improves Gastrointestinal Function in Peritoneal Dialysis Patients

Not Applicable
Recruiting
Conditions
Gastrointestinal Function
Peritoneal Dialysis
Quality of Life
Chronic Kidney Diseases
Exercise
First Posted Date
2024-04-16
Last Posted Date
2024-04-16
Lead Sponsor
Sichuan Academy of Medical Sciences
Target Recruit Count
132
Registration Number
NCT06368713
Locations
🇨🇳

Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital,School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China

Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke

Not Applicable
Active, not recruiting
Conditions
Acute Ischemic Stroke
Alteplase
Endovascular Treatment
Basilar Artery Occlusion
Thrombosis
Interventions
Procedure: Endovascular treatment
Drug: Intravenous thrombolysis (Alteplase)
First Posted Date
2022-11-30
Last Posted Date
2025-07-02
Lead Sponsor
Sichuan Academy of Medical Sciences
Target Recruit Count
340
Registration Number
NCT05631847
Locations
🇨🇳

Banan Hospital Affiliated to Chongqing Medical University, Chongqing, Chongqing, China

🇨🇳

Chongqing Sanbo Chang'an Hospital, Chongqing, Chongqing, China

🇨🇳

Chongqing University Affiliated S Central Hospital, Chongqing, Chongqing, China

and more 93 locations

Metabolomics Dynamics Study for Severe Patient

Conditions
Age:18-70 Years
Acute Physiology And Chronic Health Evaluation(APACHE)II>10
Acute Severe Disease
First Posted Date
2014-06-17
Last Posted Date
2017-04-28
Lead Sponsor
Sichuan Academy of Medical Sciences
Target Recruit Count
600
Registration Number
NCT02164786
Locations
🇨🇳

Sichuan Academy of Medical Sciences, Chengdu, Sichuan, China

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath